Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal hemoglobinuria: Interim data from a phase 2 open-label proof-of-concept study

被引：0
|
作者：
Browett, Peter [1 ]
Kulasekararaj, Austin [2 ,3 ]
Notaro, Rosario [4 ,5 ]
Ogawa, Masayo [6 ]
Risitano, Antonio [7 ,8 ]
Yu, Ji [6 ]
Lee, Jong Wook [9 ]
机构：
[1] Univ Auckland, Auckland, New Zealand
[2] Kings Coll Hosp NHS Fdn Trust, NIHR Wellcome Kings Clin Res Facil, London, England
[3] Kings Coll London, London, England
[4] Azienda Osped Univ Careggi, Florence, Italy
[5] Inst Studio Prevenz & Rete Oncol, Florence, Italy
[6] Alexion, AstraZeneca Rare Dis, Boston, MA USA
[7] Federico II Univ Naples, Naples, Italy
[8] AORN Moscati, Avellino, Italy
[9] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Seoul, South Korea
来源：
IMMUNOBIOLOGY | 2023年 / 228卷 / 05期
关键词：
D O I：
10.1016/j.imbio.2023.152638
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
188
引用
收藏
页码：80 / 80
页数：1
相关论文
共 50 条
  • [1] Vemircopan (ALXN2050) Monotherapy in Paroxysmal Nocturnal Hemoglobinuria: Interim Data from a Phase 2 Open-Label Proof-of-Concept Study
    Browett, Peter J.
    Kulasekararaj, Austin
    Notaro, Rosario
    Ogawa, Masayo
    Risitano, Antonio
    Yu, Ji
    Lee, Jong Wook
    BLOOD, 2022, 140
  • [2] Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal haemoglobinuria: Interim data from phase 2 Open-Label Proof-of-Concept study
    Browett, P.
    Kulasekararaj, Austin
    Notaro, R.
    Ogawa, M.
    Risitano, A.
    Yu, J.
    Lee, J. W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 38 - 38
  • [3] Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study
    Jang, Jun Ho
    Wong, Lily
    Ko, Bor-Sheng
    Yoon, Sung-Soo
    Li, Katie
    Baltcheva, Irina
    Nidamarthy, Prasanna Kumar
    Chawla, Raghav
    Junge, Guido
    Yap, Eng Soo
    BLOOD ADVANCES, 2022, 6 (15) : 4450 - 4460
  • [4] Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study
    Zhang, Fengkui
    Han, Bing
    Zhang, Li
    Zhao, Xin
    BLOOD, 2024, 144 : 2689 - 2689
  • [5] Nocturnal Asthma: Proof-of-Concept Open-Label Study with Delayed-Release Prednisone
    Alavoine L.
    Taillé C.
    Ball J.
    Knauer C.
    Witte S.
    Kent J.
    Aubier M.
    Pulmonary Therapy, 2015, 1 (1) : 43 - 52
  • [6] A PHASE 2 OPEN-LABEL PROOF OF CONCEPT STUDY OF THE ORAL, SMALL MOLECULE FACTOR D INHIBITOR, ACH-4471, IN UNTREATED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Risitano, A.
    Kulasekararaj, A.
    Lee, J. W.
    Notaro, R.
    Brodsky, R. A.
    Huang, M.
    Geffner, M.
    Browett, P.
    HAEMATOLOGICA, 2019, 104 : 4 - 4
  • [7] A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy
    Kulasekararaj, Austin
    Risitano, Antonio M.
    Maciejewski, Jaroslaw P.
    Notaro, Rosario
    Browett, Peter
    Lee, Jong-Wook
    Huang, Mingjun
    Geffner, Michael
    Brodsky, Robert A.
    BLOOD, 2019, 134
  • [8] Natalizumab in progressive MS Results of an open-label, phase 2A, proof-of-concept trial
    Christensen, Jeppe Romme
    Ratzer, Rikke
    Bornsen, Lars
    Lyksborg, Mark
    Garde, Ellen
    Dyrby, Tim B.
    Siebner, Hartwig R.
    Sorensen, Per S.
    Sellebjerg, Finn
    NEUROLOGY, 2014, 82 (17) : 1499 - 1507
  • [9] Ravulizumab reduces the risk of thrombosis in adult patients with paroxysmal nocturnal hemoglobinuria and high disease activity: 2-year data from a Phase 3, open-label study
    Roeth, A.
    de latour, Peffault R.
    Hill, A.
    Fuereder, W.
    Piatek, C.
    Griffin, M.
    Ogawa, M.
    Wang, J.
    Usuki, K.
    Lee, J. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 165 - 165
  • [10] A phase 2, open-label study evaluating the safety and efficacy of combination pozelimab and cemdisiran therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab
    Kelly, Richard J.
    Houghton, Nicola
    Munir, Talha
    Muus, Petra
    Youngs, Nora
    Aurand, Lisa
    Senk, Brian
    Pavani, Rodrigo
    Perlee, Lorah
    Souttou, Amal
    Griffin, Morag
    IMMUNOBIOLOGY, 2023, 228 (05) : 6 - 6
12345